AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis

By Yahoo! Finance | Nov 8, 2024 at 08:53 AM EST

Tezspire has shown significant reduction in nasal polyp size and congestion in a study. It's being evaluated for severe chronic rhinosinusitis with nasal polyps and approved for severe asthma. Further research on its effectiveness for COPD is ongoing.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.